The MTAP gene is codeleted with the tumor suppressor gene CDKN2A in multiple cancer types, causing sensitivity to inhibition of the protein methyltransferase PRMT5 (37, 38), and several PRMT5 inhibitors are being tested in clinical trials. The gene discussed is PRMT5; the disease is cancer.